Ascentage raises US$150m to fund new cancer drugs
Print Edition
SUZHOU-BASED Ascentage Pharma said it has raised US$150 million in series C funding for its pipeline of innovative cancer drugs as Chinese drug developers move to turn lab work into new drug launches in the world’s largest pharmaceutical market.
The new financing will be used to fund its R&D and manufacturing facilities as well as new hiring at a time when the government is urging the introduction of innovative treatments for prevalent severe diseases, such as cancer and cardiovascular diseases, by encouraging startups in the pharmaceutical industry.
Ascentage plans to build its team up to 300 members within six months, and 400 by the end of next year.
“With this financing, we are well positioned to achieve key data milestones as we continue to advance our growing pipeline of novel small molecule candidates,” said Chairman and CEO Yang Dajun.
The latest round takes the total amount of capital raised by Ascentage to date to US$240 million, and was led by existing investors YuanMing Prudence Fund and Oriza Seed Venture Capital, as well as new investor Teng Yue Partners.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
